Faeth Therapeutics (FTH) CFO adds 13,634 shares via trust purchases

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported open-market purchases of a total of 13,634 shares of common stock over three days. On June 29 and 30, 2026, and July 1, 2026, the trust bought multiple blocks of shares at weighted average prices disclosed in the filing, including 4,400 shares at $23.40 and 4,255 shares at $24.98. Following the latest transaction, the trust holds 46,688 shares of Faeth Therapeutics common stock. The footnotes state that Stephenson is the sole trustee of the revocable trust, with sole voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Buyer: 13,634 shares ($326,127)

Net Buy 6 txns

Insider STEPHENSON BRIAN C

Role Chief Financial Officer

Bought 13,634 shs ($326K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4,400	$23.40	$103K
Purchase	Common Stock	600	$24.22	$15K
Purchase	Common Stock	1,910	$22.95	$44K
Purchase	Common Stock	1,638	$23.88	$39K
Purchase	Common Stock	4,255	$24.98	$106K
Purchase	Common Stock	831	$23.34	$19K

Holdings After Transaction: Common Stock — 46,088 shares (Indirect, See footnote)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Key Figures

Total shares purchased: 13,634 shares Post-transaction holdings: 46,688 shares Largest single trade: 4,400 shares +3 more

6 metrics

Total shares purchased 13,634 shares Net open-market purchases reported in this Form 4

Post-transaction holdings 46,688 shares Common stock held by Brian Stephenson Revocable Trust after July 1, 2026 trade

Largest single trade 4,400 shares Open-market purchase on July 1, 2026 at $23.40 per share

Price example $24.98 per share Weighted average price for 4,255-share purchase on June 30, 2026

Additional trade size 1,910 shares Open-market purchase on June 30, 2026 at $22.95 per share

Smaller trade size 831 shares Open-market purchase on June 29, 2026 at $23.34 per share

Key Terms

weighted average price, Revocable Trust, beneficial ownership, pecuniary interest, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Revocable Trust financial

"These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust")."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 08:10 PM Accepted by SEC EDGAR 07/01/2026 - 08:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STEPHENSON BRIAN C

(Last) (First) (Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN TEXAS 78702

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		P		831	A	$23.34(1)	33,885	I	See footnote(2)
Common Stock	06/30/2026		P		1,910	A	$22.95(3)	35,795	I	See footnote(2)
Common Stock	06/30/2026		P		1,638	A	$23.88(4)	37,433	I	See footnote(2)
Common Stock	06/30/2026		P		4,255	A	$24.98(5)	41,688	I	See footnote(2)
Common Stock	07/01/2026		P		4,400	A	$23.4(6)	46,088	I	See footnote(2)
Common Stock	07/01/2026		P		600	A	$24.22(7)	46,688	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Josiah Craver, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider buying did Faeth Therapeutics (FTH) disclose in this Form 4?

Faeth Therapeutics reported that its CFO, via the Brian Stephenson Revocable Trust, bought a total of 13,634 common shares in open-market transactions. These purchases occurred over three days and increased the trust’s indirect holdings in the company.

Over what dates did the Faeth Therapeutics (FTH) CFO-related trust buy shares?

The Brian Stephenson Revocable Trust purchased Faeth Therapeutics shares on June 29, 2026, June 30, 2026, and July 1, 2026. Each date included one or more open-market transactions in common stock, all reported together in this Form 4 filing.

How many Faeth Therapeutics (FTH) shares does the CFO-related trust hold after these trades?

After the latest reported transaction, the Brian Stephenson Revocable Trust holds 46,688 shares of Faeth Therapeutics common stock. This figure reflects the position following a 600-share purchase on July 1, 2026, as reported in the Form 4.

At what prices were the Faeth Therapeutics (FTH) shares purchased by the CFO’s trust?

The filing shows weighted average purchase prices such as $23.40 and $24.98 per share. Footnotes explain that each reported price represents a weighted average across multiple trades within specified price ranges for that transaction date.

How is the Faeth Therapeutics (FTH) CFO’s ownership structured for these shares?

The shares are held by the Brian Stephenson Revocable Trust. The Form 4 notes that Brian Stephenson is the sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.

Were the Faeth Therapeutics (FTH) transactions open-market purchases or another type?

Each reported transaction is coded as “P” for an open-market or private purchase of common stock. The normalized data describes them as open-market purchases, indicating routine buying activity rather than option exercises or gifts.